The Centers for Medicare & Medicaid Services (CMS) issued a final rule on November 4, 2026, that sets a lower Medicare outpatient payment rate for drugs hospitals buy through the federal 340B discount program. The rule appeared in the Federal Register on November 6. For calendar year 2027, Medicare will generally value qualifying drugs at 72% of their average sales price under the hospital outpatient payment system. A lower payment base can reduce a patient's share of the drug bill. The same rule also raises some payments for services other than drugs, while speeding up a separate recovery tied to payments made years earlier.
Key facts
- The 2027 rate for qualifying 340B drugs is average sales price minus 28%, compared with the general rate of average sales price plus 6% restored in 2023.
- CMS estimates $4.35 billion less in Original Medicare drug payments and $1.1 billion less in beneficiary drug payments in the first year, alongside an equivalent increase in outpatient payments for non-drug services.
- The agency surveyed hospital drug acquisition costs from January 1 through April 7, 2026. The survey matters because the Supreme Court ruled in 2022 that HHS could not set different rates for 340B hospitals under the payment method it had used without conducting one.
- A separate reduction in the conversion factor for non-drug services rises from 0.5% in 2026 to 2% in 2027 for hospitals covered by the earlier remedy.
Why Medicare can use a different benchmark this time
Section 340B of the Public Health Service Act lets participating providers buy certain outpatient drugs from manufacturers at discounted prices. The price a hospital pays the manufacturer and the amount Medicare allows on a hospital outpatient claim are different figures. When a hospital buys a drug at a discount but Medicare pays a rate tied to a wider market benchmark, the two amounts can diverge. The November rule changes the Medicare payment calculation for qualifying purchases through the program.
The Supreme Court's 2022 decision in American Hospital Association v. Becerra explains why the way CMS sets the rate matters. The statute provides one route based on hospitals' acquisition costs, supported by survey data, and another based on the drugs' average price when acquisition-cost data are unavailable. In the second route, the agency can adjust the price-based rate, but the Court held that it could not use that authority to set a different rate for one group of hospitals. The Court ruled against the 2018 and 2019 payment rates on that basis.
| Medicare hospital outpatient policy period | General benchmark for qualifying 340B drugs | Status |
|---|---|---|
| 2018 through approximately the third quarter of 2022 | Average sales price minus 22.5% | Prior differential rate, later set aside |
| Restored in the 2023 rule | Average sales price plus 6% | General price-based rate before the 2027 change |
| Calendar year 2027 | Average sales price minus 28% | Finalized following the 2026 acquisition-cost survey |
The 2027 CMS fact sheet says the survey covered acquisition costs for separately payable drugs at hospitals paid under the outpatient system. CMS reports that prices paid for drugs acquired under 340B differed substantially from those paid outside the program. In some cases, even the patient's usual share of the Medicare payment exceeded the hospital's entire acquisition cost. The survey addresses the procedural problem identified in the earlier case. The new rate is an agency decision based on that survey, which the 2022 judgment predates.
Why a lower drug bill can coexist with higher payments elsewhere
The typical beneficiary share is 20% of the allowed amount, CMS says. At a hypothetical average sales price of $100, the two payment formulas give allowed amounts of $106 and $72. A 20% share of those amounts is $21.20 and $14.40 respectively. This illustrates the effect of the formula on one drug line. CMS's forecast of average savings of $900 in 2027 applies to beneficiaries receiving a qualifying drug in a hospital outpatient department. The amount at stake for an individual depends on the drug and the patient's cost-sharing arrangements.
The current adjustment is designed to be budget neutral within the outpatient payment system. CMS expects reductions on the drug side to be offset by higher payments for non-drug services. A hospital's mix of qualifying drugs and other outpatient services therefore matters to its exposure. A facility that administers many qualifying drugs may see a different shift in its mix of payments from one whose outpatient claims are concentrated in procedures and other services.
There is also an older balance to settle. The 2023 remedy addressed the invalidated earlier cuts and provided for about $9 billion in one-time payments after accounting for claims already reprocessed. When the earlier drug rate went down, non-drug rates had been raised to balance the system. CMS estimated that those earlier increases totalled $7.8 billion. It began recovering that amount through a 0.5% reduction in the non-drug conversion factor in 2026. The 2027 rule raises that offset to 2%, with hospitals that enrolled in Medicare after January 1, 2018, excluded. CMS expects recovery to reach the target in 2031.
In 2027, the drug rate, the current budget-neutral redistribution and the older recovery will all affect outpatient payment. The first applies to the qualifying drug line, while the other two affect payments for services outside that line. Those distinctions determine where patients and hospitals should expect to see the change in the new calendar year's claims.



